85 related articles for article (PubMed ID: 21295398)
1. The dark side of targeted therapy.
Karam JA; Wood CG
Eur Urol; 2011 Apr; 59(4):541-2. PubMed ID: 21295398
[No Abstract] [Full Text] [Related]
2. Toxicities of targeted therapy and their management in kidney cancer.
Di Lorenzo G; Porta C; Bellmunt J; Sternberg C; Kirkali Z; Staehler M; Joniau S; Montorsi F; Buonerba C
Eur Urol; 2011 Apr; 59(4):526-40. PubMed ID: 21277078
[TBL] [Abstract][Full Text] [Related]
3. Is tumor response important for renal carcinoma?
Inman BA; George DJ
Eur Urol; 2011 Jan; 59(1):16-7. PubMed ID: 20970245
[No Abstract] [Full Text] [Related]
4. Review: therapy for kidney cancer with a sarcomatoid component.
Fishman M
Clin Adv Hematol Oncol; 2011 Jan; 9(1):67-9. PubMed ID: 21326150
[No Abstract] [Full Text] [Related]
5. Noninfectious pneumonitis in a patient with renal cell carcinoma treated with everolimus.
Creel P; Moldawer NP
Oncol Nurs Forum; 2011 Mar; 38(2):125-8. PubMed ID: 21356651
[No Abstract] [Full Text] [Related]
6. [Molecular targeted therapy for advanced renal cell carcinoma].
Kanayama H
Gan To Kagaku Ryoho; 2010 Jul; 37(7):1208-13. PubMed ID: 20647700
[TBL] [Abstract][Full Text] [Related]
7. Everolimus: a new mammalian target of rapamycin inhibitor for the treatment of advanced renal cell carcinoma.
Grgic T; Mis L; Hammond JM
Ann Pharmacother; 2011 Jan; 45(1):78-83. PubMed ID: 21177421
[TBL] [Abstract][Full Text] [Related]
8. [Second-line treatment of advanced renal cell carcinoma after first-line targeted therapy].
Tomita Y
Gan To Kagaku Ryoho; 2011 Jun; 38(6):907-10. PubMed ID: 21677480
[TBL] [Abstract][Full Text] [Related]
9. [Application monitoring of the use of sorafenib in papillary renal cell carcinoma].
Schrader AJ; Hegele A; Olbert P; Buer J; Jeron A; Hofmann R
Urologe A; 2007 Sep; 46(9):1291. PubMed ID: 17668165
[No Abstract] [Full Text] [Related]
10. [Use of mTOR-inhibitors in solid tumors].
Seidel C; Grünwald V
Med Monatsschr Pharm; 2011 Apr; 34(4):116-26; quiz 127-8. PubMed ID: 21528529
[TBL] [Abstract][Full Text] [Related]
11. Emerging drugs for renal cell carcinoma.
Varella L; Rini BI
Expert Opin Emerg Drugs; 2010 Sep; 15(3):343-53. PubMed ID: 20443750
[TBL] [Abstract][Full Text] [Related]
12. Metastatic renal cell carcinoma: recent advances in the targeted therapy era.
Di Lorenzo G; Autorino R; Sternberg CN
Eur Urol; 2009 Dec; 56(6):959-71. PubMed ID: 19748725
[TBL] [Abstract][Full Text] [Related]
13. [Two cases of renal cell carcinoma with ascites after interleukin-2 therapy].
Kobori G; Maegawa M; Ushida H; Maekawa S; Inoue K; Kaneko Y; Ohmori K; Nishimura K
Hinyokika Kiyo; 2002 Jul; 48(7):455-7. PubMed ID: 12229188
[TBL] [Abstract][Full Text] [Related]
14. Molecular targeted therapies for renal cell carcinoma.
Graham SD; Warden ME; Lou J
Can J Urol; 2007 Dec; 14 Suppl 1():48-52. PubMed ID: 18163945
[TBL] [Abstract][Full Text] [Related]
15. Molecularly targeted therapies for renal cell cancer: TRAIL research advances.
Buttyan R; Mian BM
J Urol; 2007 May; 177(5):1606. PubMed ID: 17437767
[No Abstract] [Full Text] [Related]
16. Biotherapy skin reaction.
Newton S; Jackowski C; Marrs J
Clin J Oncol Nurs; 2002; 6(3):181-2. PubMed ID: 11998617
[No Abstract] [Full Text] [Related]
17. Targeted therapy and hand-foot skin reaction in advanced renal cell carcinoma.
Yang CH; Chuang CK; Hsieh JJ; Chang JW
Expert Opin Drug Saf; 2010 May; 9(3):459-70. PubMed ID: 20113155
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapy for renal cell carcinoma: a new therapeutic paradigm.
Shaheen PE; Bukowski RM
Cancer Invest; 2006 Oct; 24(6):640-56. PubMed ID: 16982470
[TBL] [Abstract][Full Text] [Related]
19. Management of mTOR inhibitor side effects.
Creel PA
Clin J Oncol Nurs; 2009 Dec; 13 Suppl():19-23. PubMed ID: 19948456
[TBL] [Abstract][Full Text] [Related]
20. Lingual angioedema associated with everolimus.
Mackenzie M; Wood LA
Acta Oncol; 2010; 49(1):107-9. PubMed ID: 20100146
[No Abstract] [Full Text] [Related]
[Next] [New Search]
